Tumour necrosis factor inhibitors and infection: What is there to know for infectious diseases physicians?
作者信息
Johnston Bl, Conly Jm
机构信息
Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia.
出版信息
Can J Infect Dis Med Microbiol. 2006 Jul;17(4):209-12. doi: 10.1155/2006/385789.
Abstract
摘要
相似文献
1
Tumour necrosis factor inhibitors and infection: What is there to know for infectious diseases physicians?
Can J Infect Dis Med Microbiol. 2006 Jul;17(4):209-12. doi: 10.1155/2006/385789.
2
Genetics of tumour necrosis factor-alpha in autoimmune, infectious, and neoplastic diseases.
J Inflamm. 1995;45(1):1-12.
3
Kinetics of tumour necrosis factor-alpha, soluble tumour necrosis factor receptors, interleukin 1-beta and its receptor antagonist during serious infections.
Eur J Clin Microbiol Infect Dis. 1994;13 Suppl 1:S12-6. doi: 10.1007/BF02390680.
4
Therapeutic drug monitoring of tumour necrosis factor inhibitors in the management of chronic inflammatory diseases.
Ann Clin Biochem. 2019 Jan;56(1):28-41. doi: 10.1177/0004563218782286. Epub 2018 Jun 18.
5
Herpes zoster infection risk in patients with rheumatoid arthritis on tumour necrosis factor inhibitors.
Ann Rheum Dis. 2013 May;72(5):e4. doi: 10.1136/annrheumdis-2013-203450. Epub 2013 Mar 5.
6
Tumour necrosis factor inhibitors--what we need to know.
N Z Med J. 2006 Dec 1;119(1246):U2336.
7
Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study.
BMJ. 2015 Jun 5;350:h2809. doi: 10.1136/bmj.h2809.
8
[Granulomatous diseases and pathogenic microorganism].
Kekkaku. 2008 Feb;83(2):115-30.
9
Defibrotide protects endothelial cells, but not L929 tumour cells, from tumour necrosis factor-alpha-mediated cytotoxicity.
J Pharm Pharmacol. 1995 Mar;47(3):250-2. doi: 10.1111/j.2042-7158.1995.tb05789.x.
10
[Risk of infection during treatment with tumor necrosis factor-alpha inhibitors].
Z Rheumatol. 2006 Feb;65(1):24-8, 30-1. doi: 10.1007/s00393-005-0018-z.
引用本文的文献
1
Methionine enkephalin upregulates the immune function of RAW264.7 cells to inhibit the infection of Nelson Bay orthoreoviruses.
Sci Rep. 2025 Aug 26;15(1):31380. doi: 10.1038/s41598-025-16284-y.
2
Proteomics analysis of methionine enkephalin upregulated macrophages against infection by the influenza-A virus.
Proteome Sci. 2023 Apr 11;21(1):4. doi: 10.1186/s12953-023-00205-w.
3
Small-molecule screening identifies Syk kinase inhibition and rutaecarpine as modulators of macrophage training and SARS-CoV-2 infection.
Cell Rep. 2022 Oct 4;41(1):111441. doi: 10.1016/j.celrep.2022.111441. Epub 2022 Sep 15.
4
Distinct Role of TNFR1 and TNFR2 in Protective Immunity Against Infection in Mice.
Front Immunol. 2022 Apr 11;13:867924. doi: 10.3389/fimmu.2022.867924. eCollection 2022.
5
Bioactive Diterpenes, Norditerpenes, and Sesquiterpenes from a Formosan Soft Coral sp.
Pharmaceuticals (Basel). 2021 Dec 1;14(12):1252. doi: 10.3390/ph14121252.
6
Cytokine TNF-α and its receptors TNFRI and TNFRII play a key role in the in vitro proliferative response of BLV infected animals.
Vet Res Commun. 2021 Dec;45(4):431-439. doi: 10.1007/s11259-021-09825-z. Epub 2021 Aug 27.
7
Characterization of Iturin V, a Novel Antimicrobial Lipopeptide from a Potential Probiotic Strain Lactobacillus sp. M31.
Probiotics Antimicrob Proteins. 2021 Dec;13(6):1766-1779. doi: 10.1007/s12602-021-09796-2. Epub 2021 May 13.
8
Targeting of Nanotherapeutics to Infection Sites for Antimicrobial Therapy.
Adv Ther (Weinh). 2019 Nov;2(11). doi: 10.1002/adtp.201900095. Epub 2019 Sep 26.
9
Developing Rapid Antimicrobial Susceptibility Testing for Motile/Non-Motile Bacteria Treated with Antibiotics Covering Five Bactericidal Mechanisms on the Basis of Bead-Based Optical Diffusometry.
Biosensors (Basel). 2020 Nov 19;10(11):181. doi: 10.3390/bios10110181.
10
Honey Bee Pollen in Meagre () Juvenile Diets: Effects on Growth, Diet Digestibility, Intestinal Traits, and Biochemical Markers Related to Health and Stress.
Animals (Basel). 2020 Jan 31;10(2):231. doi: 10.3390/ani10020231.
本文引用的文献
1
Efficacy and safety of the anti-TNF biologic agents.
Mod Rheumatol. 2004;14(2):101-12. doi: 10.1007/s10165-004-0275-8.
2
Differentiating the new rheumatoid arthritis biologic therapies.
J Clin Rheumatol. 2003 Apr;9(2):99-114. doi: 10.1097/01.RHU.0000062513.64012.1d.
3
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.
JAMA. 2006 May 17;295(19):2275-85. doi: 10.1001/jama.295.19.2275.
4
Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis.
Arthritis Rheum. 2006 Apr 15;55(2):333-7. doi: 10.1002/art.21841.
5
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial.
Arthritis Rheum. 2006 Apr;54(4):1075-86. doi: 10.1002/art.21734.
6
Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?
World J Gastroenterol. 2006 Feb 14;12(6):974-6. doi: 10.3748/wjg.v12.i6.974.
7
West nile virus meningoencephalitis and acute flaccid paralysis after infliximab treatment.
J Rheumatol. 2006 Jan;33(1):191-2. Epub 2005 Dec 1.
8
Immunosuppression related to collagen-vascular disease or its treatment.
Proc Am Thorac Soc. 2005;2(5):456-60. doi: 10.1513/pats.200508-091JS.
9
Infections in patients with rheumatoid arthritis treated with biologic agents.
Arthritis Rheum. 2005 Nov;52(11):3403-12. doi: 10.1002/art.21386.
10
Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use.
Diagn Microbiol Infect Dis. 2005 Nov;53(3):233-8. doi: 10.1016/j.diagmicrobio.2005.06.006. Epub 2005 Oct 24.
Zotero 插件